George A Alexandrides

6818228, Nov 16, 2004

Jun 21, 1996

08/667503

Neill B. Walsdorf - San Antonio TX
Cindy L. Wabner - Canyon Lake TX
George Alexandrides - San Antonio TX

Mission Pharmacal Company - San Antonio TX

A61K 920

424464, 424646, 424647, 424648, 514904, 514905

A vitamin and mineral supplement containing ULTRADENSEâ calcium citrate and carbonyl iron for use in humans. Calcium in the form of citrate enhances absorption of iron, zinc, and magnesium. ULTRADENSEâ calcium citrate provides more bioavailable calcium than usual preparations of calcium citrate. Carbonyl iron provides iron in a form that significantly reduces the risk to children of accidental iron poisoning from formulations that provide iron in salt form. The supplement may further contain a number of vitamins and minerals in a tablet that is elegantly small, weighing about 1. 5-1. 6 g. The small size allows ease of swallowing and encourages patient acceptability. Methods of making such a supplement and methods of treating maladies in need of vitamin and mineral supplementation are provided.

6887897, May 3, 2005

Jul 31, 2001

09/919025

George Alexandrides - San Antonio TX, US

Mission Pharmacal Company - San Antonio TX

A61K031/28
A61K031/194

514492, 514557, 514574, 514578, 514891

Methods of controlling calcium intake and phosphate metabolism and metabolic acidosis in patients suffering from renal failure and associated hyperphosphatemia or patients predisposed to development of a hyperphosphatemic condition are provided. The method in accordance with this invention comprises administering to a patient a calcium glutarate compound. Therapeutic benefit can be realized in accordance with such method by administering the compound orally to a patient to increase available calcium and contact and bind with ingested phosphate in the patient's digestive tract, and thereby prevent its intestinal absorption.

52198898, Jun 15, 1993

Dec 3, 1991

7/803689

Neill B. Walsdorf - San Antonio TX
George Alexandrides - San Antonio TX
Charles Y. C. Pak - Dallas TX

The University of Texas System - Austin TX
Mission Pharmacal Company - San Antonio TX

A61K 3119

514574

A method for supplementing dietary potassium, magnesium and citrate is disclosed that comprises orally administering an effective amount of potassium magnesium citrate in a single salt. Methods for decreasing urinary calcium and oxalate by the administration of potassium magnesium citrate in a single salt are also disclosed.

49855930, Jan 15, 1991

Jan 5, 1988

7/140818

Neill B. Walsdorf - San Antonio TX
George Alexandrides - San Antonio TX

Mission Pharmacal Company, Inc. - San Antonio TX

C07C 59265

562584

A dual mineral salt consisting essentially of magnesium, potassium and citrate. A method for manufacturing the subject salt in a form having a bulk density ranging from about 1. 0 g/cc to about 1. 3 g/cc is also disclosed, and the use of the subject salt as a dietary supplement are also disclosed.

62876074, Sep 11, 2001

Jul 19, 1999

9/356649

Charles Y. C. Pak - Dallas TX
George Alexandrides - San Antonio TX
Neill B. Walsdorf - San Antonio TX

Mission Pharmacal Company - San Antonio TX
Board of Regents, University of Texas System - Austin TX

A61K 3306
A61K 31194
A61K 3300

424682

A composition useful as a dietary supplement for providing potassium, calcium, and citrate is presented, as well as processes for producing the composition, and methods for using the composition as a dietary supplement. Administration of the composition counters bone loss associated with aging or menopause by providing bioavailable calcium and, simultaneously, delivering alkali load. In addition, administration of the composition produces a substantial increase in urinary citrate, which counters kidney-stone formation.

50754998, Dec 24, 1991

Nov 21, 1988

7/275046

Neill B. Walsdorf - San Antonio TX
George Alexandrides - San Antonio TX
Charles Y. C. Pak - Dallas TX

Board of Regents, The University of Texas System - Austin TX
Mission Pharmacal Company - San Antonio TX

C07C 5500
A61K 3119

562590

One aspect of the present invention includes the novel compound having the formula: Ca. sub. 2 (OOC--CH. sub. 2 --COHCOO-CH. sub. 2 COO)(CH. sub. 3 CHOH-COO) In another aspect of the present invention, a method is provided for the treatment of a calcium related pathology. The inventive method includes the steps of providing a pharmaceutically acceptable composition, including as the active principle the compound dicalcium citrate-lactate, and administering to an individual in need thereof a therapeutically effective amount of said pharmaceutically acceptable composition. In yet another aspect of the present invention, a process is provided for producing the compound dicalcium citrate-lactate. The inventive process comprising the steps of: (a) admixing stoichiometric quantities of citric acid and a calcium compound selected from the group consisting of calcium carbonate, calcium oxide and calcium hydroxide; (b) initiating a reaction by admixing stoichiometric quantities of lactic acid and water with said citric acid and calcium compound of step (a); (c) mixing the reactance of step (b) to produce a dense, hydrated mixture comprising calcium ions, citrate ions and lactate ions in a ratio of about 2:1:1; and (d) dehyrating the dense, hydrated mixture of step (c).

48141771, Mar 21, 1989

Aug 13, 1986

6/896651

Neill B. Walsdorf - San Antonio TX
George Alexandrides - San Antonio TX
Charles Y. C. Pak - Dallas TX

Board of Regents, University of Texas System - Austin TX
Mission Pharmacal - San Antonio TX

A61K 920
A61K 3300
A61K 3306

424464

A calcium citrate composition having a bulk density greater than about 1. 1 g/cc. Citric acid and a calcium compound are mixed to produce a mixture having a calcium compound/citric acid molar ratio of about 1. 5. A hydrated mixture percent is produced by agitatively adding water to the mixture, although when desired the calcium compound, citric acid and water may BACKGROUND OF THE INVENTION A portion of the development of the present invention was supported by Grant No. P01-AM 20543 from the United States Government, National Institutes of Health.

54322006, Jul 11, 1995

Apr 12, 1993

8/046013

Neill B. Walsdorf - San Antonio TX
George Alexandrides - San Antonio TX
Charles Y. C. Pak - Dallas TX

A61K 3119

514574

A method for supplementing dietary potassium, magnesium and citrate is disclosed that comprises orally administering an effective amount of potassium magnesium citrate in a single salt. Methods for decreasing urinary calcium and oxalate by the administration of potassium magnesium citrate in a single salt are also disclosed.